Combination therapy shows promise against HER2-positive metastatic breast cancer
Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology.
More... |
Re: Combination therapy shows promise against HER2-positive metastatic breast cancer
"... offers a 'chemotherapy-free' option..." - sounds good!
|
All times are GMT -7. The time now is 09:07 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021